CTMedic - Right, that's why maybe the trial analys
Post# of 148102
(Total Views: 398)
Posted On: 02/16/2021 1:39:24 PM
CTMedic - Right, that's why maybe the trial analysts and the FDA are taking the time to evaluate the post-28 day mortality rates for both arms. In looking at the chart 5 from the aviptadil trial results, looks like the 28-42 day mortality represents the lion's share of the 28-77 day rate.
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼